CME Group (CME) came out with quarterly earnings of $2.68 per share, beating the Zacks Consensus Estimate of $2.65 per share. This compares to earnings of $2.25 per share a year ago.
A diverse product portfolio, increased volatility and a strong market position are likely to have aided CME's performance in the third quarter.
Evaluate the expected performance of CME (CME) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
CME (CME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Added new longs: CME Group, CompoSecure, and Mitsubishi Heavy Industries during early August market dip; exited Finning and reduced Garmin and Kongsberg due to full valuations. CME Group is undervalued with strong potential due to its monopoly-like position in derivatives markets and resilience against new competition. CompoSecure benefits from a transformative transaction with David Cote, enhancing financial structure and strategic direction, making shares attractive despite prior SPAC stigma.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
CME Group's dominant market position and high profitability make it a crucial player in global finance, particularly in derivatives and futures trading. The company's exceptional free cash flow margin of 60.30% and consistent dividend growth make it an attractive option for dividend investors. Despite its strong fundamentals, CME Group is currently rated as a hold due to its high valuation, with a fair value estimate of $211.27 per share.
U.S. Treasury yields were slightly higher early Monday as investors assessed future moves from the Federal Reserve following Friday's bumper jobs report.
Here's today's Final Trades from the Investment Committee.
Solid global presence, a compelling product portfolio, increased electronic trading and a focus on over-the-counter clearing services poise CME Group for growth.
CME (CME) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
I explore the idea of managing a highly concentrated portfolio and share how I narrowed down my highest-conviction dividend investments to just five stocks. I emphasize the importance of choosing reliable companies, future-proof wealth compounders, even in a compact portfolio with limited stock picks. After careful analysis, I present my top five dividend stocks, each chosen for their unique qualities, strong growth potential, and ability to thrive long-term.